Showing results (11-20 of 55) with videos related to

Sort By:
Pageof 6
Journal of Proteome Research|March 4, 2006
Proteomic analysis of human immunodeficiency virus using liquid chromatography/tandem mass spectrometry effectively distinguishes specific incorporated host proteinsAndrew C S Saphire, Philippe A Gallay, Steven J Bark
Antiviral Research|October 5, 2013
Host-targeting agents in the treatment of hepatitis C: a beginning and an end?James M Baugh, Jose A Garcia-Rivera, Philippe A Gallay
The Journal of General Virology|January 29, 2010
Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexesUdayan Chatterji, Michael D Bobardt, Precious Lim, et al.
Plos One|July 22, 2016
Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a ReinfectionUdayan Chatterji, Michael Bobardt, Lana Schaffer, et al.
The Journal of Biological Chemistry|October 22, 2004
Cyclophilin-A is bound through its peptidylprolyl isomerase domain to the cytoplasmic dynein motor protein complexMario D Galigniana, Yoshihiro Morishima, Philippe A Gallay, et al.
Antimicrobial Agents and Chemotherapy|February 11, 2015
Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factoriesUdayan Chatterji, Michael Bobardt, Andrew Tai, et al.
Antimicrobial Agents and Chemotherapy|May 5, 2010
Syndecan-Fc hybrid molecule as a potent in vitro microbicidal anti-HIV-1 agentMichael D Bobardt, Udayan Chatterji, Lana Schaffer, et al.
The Journal of Biological Chemistry|October 10, 2006
Trim5alpha accelerates degradation of cytosolic capsid associated with productive HIV-1 entryUdayan Chatterji, Michael D Bobardt, Peter Gaskill, et al.
Plos One|April 23, 2016
Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175Philippe A Gallay, Udayan Chatterji, Michael D Bobardt, et al.
Antimicrobial Agents and Chemotherapy|May 16, 2012
The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexesSam Hopkins, Michael Bobardt, Udayan Chatterji, et al.
Pageof 6